Stock INTEG B INTEGRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Integrum AB

Equities

INTEG B

SE0009807266

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
54.8 SEK +2.62% Intraday chart for Integrum AB +2.62% +20.04%
06-13 Integrum AB Signs Memorandum of Understanding with Coapt, LLC for the Use of its Pattern Recognition Technology with the e-OPRA[TM] Implant System CI
06-10 Integrum AB Enters Collaboration and Distribution Agreement with Hanger CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • With an expected P/E ratio at 747.31 and 192.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INTEGRUM AB Stock Integrum AB
+20.04% 97.49M -
SONOVA HOLDING AG Stock Sonova Holding AG
+1.17% 18.32B
A
COCHLEAR LIMITED Stock Cochlear Limited
+11.21% 14.19B
B
DEMANT A/S Stock Demant A/S
+1.82% 9.52B
B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-23.29% 1.95B -
EMBLA MEDICAL HF. Stock Embla Medical hf.
+7.47% 1.76B
B+
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+0.35% 1.21B
D-
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
0.00% 526M -
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 365M - -
DELCATH SYSTEMS, INC. Stock Delcath Systems, Inc.
+101.20% 229M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. INTEG B Stock
  4. Ratings Integrum AB